Monday, January 22, 2018 10:15 PM ET
Insider Sale at CymaBay Therapeutics (CBAY) Continues Selling Trend
A SEC filing today disclosed a substantial insider sale of CymaBay Therapeutics shares as — Kurt von Emster, Director — sold 144,216 shares in the company having a market value of approximately $1,477,669. There have been 2 insiders with buy/sell transactions in the past 90 days prior to this filing. These trades have resulted in the acquisition of 5,000 company shares and the disposition of 291,069 company shares over this time period. Adding the most recent activity to this 90-day history indicates insider trades have been net sales of 430,285 shares and have averaged 146,762 shares per transaction over this time period.
The number of insider buy/sell trades at CymaBay Therapeutics is higher than that of the 280 peer company average over the last 90-day period. The Bio Therapeutic Drugs peer group saw 336 buy/sell trades during this period for an average of 1.2 transactions per company. However, the number of shares traded per transaction by CymaBay Therapeutics insiders is lower than its peers. Within the peer group there were 44,054,825 shares purchased and 42,104,485 shares sold with company insiders acquiring 8,988 shares on average over this time period.
The data used in creating and writing in this story eliminates all trading activity reported to the SEC that involves awards, options, exercise of derivative securities, company buy-backs, taxes, gifts, shares acquired via inheritance and tenders or exchange offers.
Using proprietary Natural Language Generation (NLG) technology, UpTick evaluates corporate insider filings reported to the SEC and creates real-time news and analysis to report the most significant insider transactions based on transaction type, size and historical trends.
For more information, contact UpTick at firstname.lastname@example.org. Copyright 2018 UpTick Data Technologies. All rights reserved.